In summary, this study employed an isogenic murine system with subsequent validation in multiple patient cohorts to demonstrate that PBRM1 loss decreases IFNγ dependent signaling and tumor immunogenicity, and suggest that PBRM1 mutation associates with ICB resistance. Here, PBRM1 is linked to neoplasm.